Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Media Is Abbott's January Pullback a Good Time to Buy? By Thomas Hughes. Publication Date: 1/24/2026. 
Quick Look - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 pullback has made its stock look attractively valued. The move — driven more by market angst than by any company-specific weakness — appears to be a knee-jerk overreaction that has pushed the stock back into a buy zone. 
Gold is soaring, but while the media hypes price predictions, there's one gold income opportunity no one's talking about. It's not a mining stock, not an option trade, and not physical gold you have to store. A quiet fund trading for just $15 has been delivering up to $1,152 a month to regular investors. It's a smarter, faster way to ride gold's surge and get paid monthly while you do it. Discover the gold income breakthrough most investors are missing. That zone corresponds to price action from 2022–2024, when Abbott was recovering from a post-COVID revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates Although a few metrics missed expectations in Abbott Laboratories' Q4 results and guidance, revenue of $11.46 billion rose 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth lagged consensus by several hundred basis points, but stronger margins helped offset that: adjusted earnings per share (EPS) increased 12%, slightly above estimates. By segment, the results highlighted the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted—Nutrition fell nearly 9%—but solid growth in Established Pharmaceuticals and Med Tech more than offset those declines. Established Pharmaceuticals grew about 9%, driven by generics and emerging markets; Med Tech rose roughly 12.3%, with strength across its subsegments. Margins improved, though they slightly missed some analyst forecasts. Product-mix shifts, Med Tech strength, reduced COVID-19 sales, and operational improvements collectively boosted margins. Management expects these trends to continue, forecasting earnings growth around 10% in 2026—outpacing revenue—and supporting its capital-return plans. Abbott's capital returns are central to the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and it appears positioned to continue that trend. After the pullback the stock yields about 2.5%, and the company pays out less than half of consensus earnings, leaving ample cash flow for share buybacks, which help offset dilution from share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but no major rating or price-target changes were announced the morning of the release. The prevailing view remains that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth. MarketBeat's consensus price target implies as much as roughly 30% upside, potentially pushing the stock to new all-time highs; even the low-end target suggests modest upside. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion, and acquisitions. For example, the proposed acquisition of Exact Sciences would broaden Abbott's revenue and profit streams and expand its product pipeline. The recent decline has been sharp and could deepen, but institutions accumulated shares throughout 2025 and are likely buyers at these discounted levels. Early technical support appears around $105–$110, though it is not yet confirmed. Shares could dip to the low end of the target buy zone—possibly to about $95 or lower—before rebounding.
| 
